People: Genoptix, Inc. (GXDX.O)

GXDX.O on Nasdaq

31.34USD
9 Feb 2010
Price Change (% chg)

$0.09 (+0.29%)
Prev Close
$31.25
Open
$31.52
Day's High
$31.77
Day's Low
$31.13
Volume
138,502
Avg. Vol
510,686
52-wk High
$38.13
52-wk Low
$24.15

view people for:

Summary

Name Age Since Current Position
Senyei, Andrew 59 2000 Chairman of the Board
Nova, Tina 55 2000 President, Chief Executive Officer, Director
Schuling, Douglas 48 1999 Chief Financial Officer, Senior Vice President
Riccitelli, Samuel 50 2001 Chief Operating Officer, Executive Vice President
Kuhlen, Christian 36 2007 Vice President, General Counsel, Corporate Secretary
Buono, Timothy 43 2000 Director
Curry, Robert 62 2002 Director
Henos, Michael 59 2001 Director
Eastham, Karin 59 2008 Director
McCarthy, Laurence 64 2008 Director
White, Christine 57 2009 Director
» Insider Trading

Biographies

Name Description
Senyei, Andrew Mr. Andrew E. Senyei, M.D. has served as Chairman of the Board of Genoptix, Inc since April 2000. Dr. Senyei has been a managing director and a general partner of Enterprise Partners, a venture capital firm, since 1987. Dr. Senyei was a founder of Molecular Biosystems and, prior to joining Enterprise Partners, was a practicing clinician and adjunct associate professor of obstetrics, gynecology and pediatrics at the University of California, Irvine. He serves on the boards of directors of numerous private healthcare companies. Dr. Senyei obtained his M.D. from Northwestern University and residency training at the University of California Irvine, Medical Center.
Nova, Tina Ms. Tina Nova Bennett, Ph.D. has served as President and Chief Executive Officer, and a member of Board of Directors, since March 2000. From 1994 to January 2000, Dr. Nova Bennett served as chief operating officer and president of Nanogen, Inc., a provider of molecular diagnostic tests, where she was a co-founder. From 1992 to 1994, Dr. Nova Bennett served as chief operating officer of Selective Genetics, a targeted therapy biotechnology company. She currently serves as a member of the board of directors of Arena Pharmaceuticals, Inc. and Cypress Bioscience, Inc., both publicly held clinical-stage biopharmaceutical companies. She also serves on the board of trustees of the University of San Diego and is a life science sector representative to the Independent Citizen's Oversight Committee overseeing the California Stem Cell Initiative (Proposition 71). Dr. Nova Bennett holds a B.S. degree in biological sciences from the University of California, Irvine and a Ph.D. in biochemistry from the University of California, Riverside.
Schuling, Douglas Mr. Douglas A. Schuling has served as Senior Vice President and Chief Financial Officer since April 1999. From 1997 to March 1999, Mr. Schuling held the position of chief financial and operating officer for Point-of-Care Systems, a venture capital backed clinical information systems company. From 1985 to 1997, Mr. Schuling held various positions at Nellcor Puritan Bennett, a research, development and manufacturing company, specializing in medical equipment and supplies, most recently as Hospital Group Controller. Mr. Schuling received his B.S. degree in accounting from Drake University.
Riccitelli, Samuel Mr. Samuel D. Riccitelli has served as Executive Vice President and Chief Operating Officer of Genoptix, Inc since October 2001. From 1995 to 2001, Mr. Riccitelli served in a number of positions for Becton, Dickinson and Company, a global medical technology company, including most recently as vice president & general manager and as a board member for BD Ventures, L.L.C., a venture capital fund. From 1989 to 1994, he served in a number of positions for the FOxS Division of Puritan-Bennett Corporation, a medical device company, including most recently as general manager. Mr. Riccitelli holds a B.A. in biology from Washington and Jefferson College and a M.S. Eng. degree in mechanical & biomedical engineering from The University of Texas.
Kuhlen, Christian Mr. Christian V. Kuhlen has served as Vice President, General Counsel and Corporate Secretary of Genoptix, Inc since September 2007. Prior to joining Genoptix, Dr. Kuhlen was an attorney in private practice as an associate with Cooley Godward Kronish LLP from October 2004 to September 2007. Between August 1997 and May 2004, Dr. Kuhlen was a full-time graduate student. From October 1995 to July 1997, Dr. Kuhlen was a research assistant at The Scripps Research Institute in La Jolla, California, where he studied the pathogenesis of the hepatitis B and hepatitis C viruses. He holds a B.S. in biochemistry and cell biology and a B.A. in economics from the University of California, San Diego and a J.D. and M.D. from the University of Southern California.
Buono, Timothy Mr. Timothy M. Buono has served on board of Directors of Genoptix, Inc since March 2000. Since 1997, Mr. Buono has been a vice-president of Tullis-Dickerson & Co., Inc., a healthcare focused venture capital firm, and a partner in the general partner entities of its sponsored venture capital funds. From 1994 to 1997, he served as senior vice president, business development, for Health Partners, Inc., a healthcare services company. From 1993 to 1994, Mr. Buono served as director, business development, for Occupational Health Resources, Inc., a healthcare services company. From 1990 to 1993, Mr. Buono served as an associate of Tullis-Dickerson & Co., Inc. From 1988 to 1990, Mr. Buono was a financial and operations analyst for Shaffer-Clarke. Mr. Buono is a director of a number of privately-held companies. He received his B.A. in Economics from Connecticut College in 1988, and completed an Executive Program at Columbia University's Graduate School of Business in 2003.
Curry, Robert Mr. Robert E. Curry, Ph.D. has served on board of Directors of Genoptix, Inc since February 2002. Since July 2002, Dr. Curry has served as a venture partner at Alliance Technology Ventures, L.P., based in Atlanta, Georgia. From July 2001 to July 2002, Dr. Curry was engaged as a consultant to DLJ Capital Corporation, a wholly-owned subsidiary of Credit Suisse First Boston (USA), Inc., or CSFB. He joined the Sprout Group, or Sprout, a submanager of various venture capital funds within the CSFB organization, as a general partner in May 1991. Prior to joining Sprout, Dr. Curry served in various capacities with Merrill Lynch R&D Management and Merrill Lynch Venture Capital from 1984, including as president of both organizations from January 1990 to May 1991. Previously, Dr. Curry was a vice president of Becton, Dickinson and Company, a pharmaceutical company, from May 1980 to July 1984, and General Manager of the Diagnostics Systems Division of Bio-Rad Laboratories Inc., a clinical diagnostic and life sciences research company, from August 1976 to May 1980. He currently is a director of numerous privately-held companies as well as the chairman of the board and a trustee of Keck Graduate Institute, a not-for-profit organization. He is also currently the acting chief executive officer of SensysMedical, Inc. Dr. Curry received a B.S. from the University of Illinois, and a M.S. and Ph.D. in chemistry from Purdue University.
Henos, Michael Mr. Michael A. Henos has served on board of Directors of Genoptix, Inc since 2001. From 1993 to the present, Mr. Henos has served as managing general partner of Alliance Technology Ventures, L.P., based in Atlanta, Georgia. Mr. Henos served as a general partner of Aspen Ventures, an early stage venture capital partnership, from 1991 to 2001. Mr. Henos previously served as a vice president of 3i Ventures Corporation, the predecessor of Aspen Ventures, from 1986 to 1991. From 1984 to 1986, Mr. Henos served as a healthcare consultant with Ernst & Young, specializing in venture financing of startup medical technology companies. Before joining Ernst & Young, Mr. Henos served in a variety of operating management positions and co-founded and served as chief executive officer of ProMed Technologies, Inc. Mr. Henos is the chairman of the board of directors of both Inhibitex, Inc., a publicly held clinical stage biopharmaceutical company, and AtheroGenics, Inc., a publicly held biopharmaceutical company. Mr. Henos received his B.S. and MBA from the University of California, Los Angeles.
Eastham, Karin Ms. Karin Eastham has been appointed to the Board of Directors of Genoptix, Inc. effective July 30, 2008. Karin Eastham has served as the Executive Vice President, Chief Operating Officer, and Trustee for the Burnham Institute for Medical Research since 2004. Prior to this, Ms. Eastham was the Senior Vice President of Finance and the Chief Financial Officer for Diversa Corporation. She has also served in similar senior level management roles at Combichem, Inc., Cytel Corporation and Boehringer Mannheim Diagnostics. She currently serves on the Boards of Directors for multiple life science companies including Illumina, Inc., and Amylin Pharmaceuticals, Inc. She also serves on the boards of Tercica, Inc. and SGX Pharmaceuticals, Inc., which have entered into definitive merger agreements pursuant to which such companies will be acquired by Ipsen, S.A. and Eli Lilly and Company, respectively, subject to various conditions including stockholder approval. Ms. Eastham earned her MBA in Finance and B.S. in Accounting from Indiana University and is a member of the American Institute of Certified Public Accountants and the California Society of Certified Public Accountants. Ms. Eastham is also a Certified Director.
McCarthy, Laurence Mr. Laurence R. McCarthy, Ph.D. has been appointed to the Board of Directors of Genoptix, Inc. effective July 30, 2008. Dr. McCarthy is a Venture Partner with Ampersand Ventures and President of Scientific Technologies and Solutions, LLC. Dr. McCarthy was President, CEO, Chairman and CTO of Focus Diagnostics and later served as its CTO following the company's acquisition by Quest Diagnostics. Prior to this, he was President for the U.S. Diagnostics Division of Boehringer Mannheim and Vice President and General Manager and Vice President R&D for Becton Dickinson & Co. Dr. McCarthy's academic experience includes faculty positions at Johns Hopkins School of Medicine, University of North Carolina School of Medicine, and Cornell University School of Medicine, as well as serving as a Laboratory Director at the Memorial Sloan-Kettering Cancer Center and at the North Carolina Memorial Hospital. Dr. McCarthy received his Ph.D. in Microbiology from the University of New Hampshire and his B.S. in Biology from St. Anselm College.
White, Christine Dr. Christine A. White has been elected as the Director of Genoptix, Inc. on January 6, 2009. White was with Biogen Idec Inc., a biopharmaceutical company, from 1996 to 2005, where she held several senior positions, most recently as Senior Vice President, Global Medical Affairs. From 1994 to 1996, Dr. White served as the Director of Clinical Oncology Research at the Sidney Kimmel Cancer Center in San Diego and, from 1984 to 1994, Dr. White was on the clinical staff and held various positions in the Department of Medicine at Scripps Memorial Hospitals in La Jolla and Encinitas, California, most recently as Chairman, Department of Medicine. Dr. White serves as a member of the board of directors at Arena Pharmaceuticals, Inc. and Monogram Biosciences, Inc. Dr. White holds a B.A. in Biology and an M.D. from the University of Chicago and is Board certified in both Internal Medicine and Medical Oncology.

Basic Compensation

Name Fiscal Year Total
Senyei, Andrew --
Nova, Tina 1,505,460
Schuling, Douglas 724,778
Riccitelli, Samuel 976,812
Kuhlen, Christian 527,056
Buono, Timothy --
Curry, Robert --
Henos, Michael --
Eastham, Karin --
McCarthy, Laurence --
White, Christine --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Senyei, Andrew 0 0
Nova, Tina 117,542 3,003,200
Schuling, Douglas 40,710 1,040,140
Riccitelli, Samuel 52,604 1,344,030
Kuhlen, Christian 0 0
Buono, Timothy 0 0
Curry, Robert 0 0
Henos, Michael 0 0
Eastham, Karin 0 0
McCarthy, Laurence 0 0
White, Christine 0 0

Insider Trading

Name Shares Traded Price
NOVA TINA SUSAN 1,355 $1.24
NOVA TINA SUSAN 16,700 $31.13
NOVA TINA SUSAN 15,345 $0.38
KUHLEN CHRISTIAN V 1,340 $35.32
KUHLEN CHRISTIAN V 1,340 $9.03
SCHULING DOUGLAS A 951 $0.38
SCHULING DOUGLAS A 6,631 $1.24
SCHULING DOUGLAS A 7,582 $35.71
RICCITELLI SAMUEL D 1,190 $0.38
RICCITELLI SAMUEL D 1,190 $35.00
RICCITELLI SAMUEL D 6,578 $1.24
RICCITELLI SAMUEL D 7,305 $34.29
RICCITELLI SAMUEL D 727 $0.38
NOVA TINA SUSAN 19,900 $34.69
NOVA TINA SUSAN 4,637 $0.38
NOVA TINA SUSAN 1,000 $35.44
NOVA TINA SUSAN 16,263 $1.24
RICCITELLI SAMUEL D 1,986 $35.74
KUHLEN CHRISTIAN V 736 $35.74
SCHULING DOUGLAS A 4,800 $0.00
NOVA TINA SUSAN 13,300 $0.00
RICCITELLI SAMUEL D 7,200 $0.00
SCHULING DOUGLAS A 1,534 $35.74
KUHLEN CHRISTIAN V 2,250 $0.00
NOVA TINA SUSAN 3,817 $35.74
» Full list on Insider Trading
view people for: